S'abonner

Neonatal hyperoxia promotes asthma-like features through IL-33–dependent ILC2 responses - 05/10/18

Doi : 10.1016/j.jaci.2017.11.025 
In Su Cheon, PhD a, b, Young Min Son, PhD a, b, Li Jiang, BS a, b, Nicholas P. Goplen, PhD b, Mark H. Kaplan, PhD a, Andrew H. Limper, MD b, Hirohito Kita, MD c, Sophie Paczesny, MD, PhD a, Y.S. Prakash, MD, PhD d, e, Robert Tepper, MD, PhD a, Shawn K. Ahlfeld, MD a, f, Jie Sun, PhD a, b, c,
a Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Ind 
b Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minn 
c Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minn 
d Department of Anesthesiology, Mayo Clinic College of Medicine and Science, Rochester, Minn 
e Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, Minn 
f Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 

Corresponding author: Jie Sun, PhD, Mayo Clinic, Department of Pediatrics, Indiana University School of Medicine, 201 1st St SW, Indianapolis, IN 46202.Mayo ClinicDepartment of PediatricsIndiana University School of Medicine201 1st St SWIndianapolisIN46202

Abstract

Background

Premature infants often require oxygen supplementation and, therefore, are exposed to oxidative stress. Following oxygen exposure, preterm infants frequently develop chronic lung disease and have a significantly increased risk of asthma.

Objective

We sought to identify the underlying mechanisms by which neonatal hyperoxia promotes asthma development.

Methods

Mice were exposed to neonatal hyperoxia followed by a period of room air recovery. A group of mice was also intranasally exposed to house dust mite antigen. Assessments were performed at various time points for evaluation of airway hyperresponsiveness, eosinophilia, mucus production, inflammatory gene expression, and TH and group 2 innate lymphoid cell (ILC2) responses. Sera from term- and preterm-born infants were also collected and levels of IL-33 and type 2 cytokines were measured.

Results

Neonatal hyperoxia induced asthma-like features including airway hyperresponsiveness, mucus hyperplasia, airway eosinophilia, and type 2 pulmonary inflammation. In addition, neonatal hyperoxia promoted allergic TH responses to house dust mite exposure. Elevated IL-33 levels and ILC2 responses were observed in the lungs most likely due to oxidative stress caused by neonatal hyperoxia. IL-33 receptor signaling and ILC2s were vital for the induction of asthma-like features following neonatal hyperoxia. Serum IL-33 levels correlated significantly with serum levels of IL-5 and IL-13 but not IL-4 in preterm infants.

Conclusions

These data demonstrate that an axis involving IL-33 and ILC2s is important for the development of asthma-like features following neonatal hyperoxia and suggest therapeutic potential for targeting IL-33, ILC2s, and oxidative stress to prevent and/or treat asthma development related to prematurity.

Le texte complet de cet article est disponible en PDF.

Key words : Neonatal hyperoxia, oxidative stress, asthma, IL-33, ILC2s

Abbreviations used : AHR, BPD, DC, HDM, ILC2, PAS, PN, RA, ROS, SFN, TSLP, WT


Plan


 This study was supported by grants RO1 AI112844, AG047156, and HL126647 to J.S.; RO1 AI095282, AI129241, and HL62150 to M.H.K.; RO1 HL62150 and Huvis Foundation grant to A.H.L; RO1 HL117823 and RO1 AI128729 to H.K.; R01 CA168814 to S.P.; Indiana Pediatric Scientist Award and K12 HD068371 to S.K.A; and RO1 HL056470 to Y.S.P.
 Disclosure of potential conflict of interest: M. H. Kaplan has received National Institutes of Health (NIH) grant funding. H. Kita's institution has received grant funds and has grants pending from the National Heart, Lung, and Blood Institute and the National Institute of Allergy and Infectious Diseases. S. Paczesny's institution has received grant funding from the NIH and the Leukemia Lymphoma Society (grant nos. NIH CA 168814 and LLS1293-15) and NIH research grants HD074587, HD090215, and HL139934. She holds patents and receives royalties on Methods of graft-vs-host disease licensed to Viracor-IBT Laboratories. R. Tepper's institution has received and has pending NIH grant funding. J. Sun's institution has NIH research grants (grant nos. AI112844, HL126647, and AG047156) and NIH research grant AI119612. The rest of the authors declare that they have no relevant conflicts of interest.


© 2017  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 4

P. 1100-1112 - octobre 2018 Retour au numéro
Article précédent Article précédent
  • Obstruction phenotype as a predictor of asthma severity and instability in children
  • Ronald L. Sorkness, Edward M. Zoratti, Meyer Kattan, Peter J. Gergen, Michael D. Evans, Cynthia M. Visness, Michelle Gill, Gurjit K. Khurana Hershey, Carolyn M. Kercsmar, Andrew H. Liu, George T. O'Connor, Jacqueline A. Pongracic, Dinesh Pillai, Christine A. Sorkness, Alkis Togias, Robert A. Wood, William W. Busse
| Article suivant Article suivant
  • Molecular allergy diagnostics refine characterization of children sensitized to dog dander
  • Ulrika Käck, Anna Asarnoj, Hans Grönlund, Magnus P. Borres, Marianne van Hage, Gunnar Lilja, Jon R. Konradsen

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.